New biotech facility to bring 350 jobs to Dublin

pharmafile | February 14, 2018 | News story | Manufacturing and Production, Research and Development Dublin, Ireland, MSD, pharma 

MSD has announced plans to invest in a new biotechnology facility in Dublin which it claims will create 350 jobs in the Irish capital.

The plant will be built on property the company already owns – the site of its former facility in Swords, which was closed down in June last year, taking with it 570 jobs since 2013.

The news shows that MSD is committed to bolstering its operations in Ireland. The company already employs more than 1,700 staff across four sites in Dublin, Carlow, Cork and Tipperary, with operations in the country generating $5.8 billion in 2016.  

Last year, the firm announced plans to invest just under $350 million in its Carlow and Cork sites by 2020.

The move is part of a global investment plan to the tune of $12 billion which the company announced this month, around $10 billion of which will be spent in the US.

“This investment by MSD is a great vote of confidence in Ireland. MSD has been a tremendous success story in this country with plants located in several centres, providing valuable employment,” commented Speaking Ireland’s Minister for Business, Enterprise and Innovation, Heather Humphreys. “This new, cutting edge, Biotechnology facility will be a tremendous asset to our Pharma industry and will deepen the great partnership between the company and Ireland.”

Matt Fellows

Related Content

Merck to acquire Harpoon Therapeutics for approximately $680m

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced …

markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

Owkin and Merck, known as MSD outside of the US and Canada, have announced that …

Merck to acquire Caraway Therapeutics for up to $610m

Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced …

Latest content